Qiagen Q2 Revenues Increase 5 Percent, Paced by MDx Business | GenomeWeb

The story has been updated to include comments from Qiagen's conference call on Wednesday morning.

NEW YORK (GenomeWeb) – Qiagen reported after the close of the market on Tuesday that its second quarter sales rose 5 percent year over year, matching consensus analysts' estimates on the top and bottom lines.

Qiagen recorded sales of $330.8 million, up from $315.2 million during the year-ago quarter, and on par with the average Wall Street estimate. It said that its adjusted net sales were $331.2 million, up 5 percent from $316.4 million for Q2 2013.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.